Zobrazeno 1 - 10
of 31
pro vyhledávání: ''
Autor:
Ellinor Elinder, Jonas Bergh, Anne Andersson, Henrik Lindman, Jamila Adra, Yvonne Brandberg, Mats Hellström, Thomas Hatschek, Hemming Johansson, Aglaia Schiza, Hanna Fredholm, Ann Charlotte Dreifaldt, Edward Azavedo, Lena M. S. Carlsson, Ioannis Zerdes, Erika Isaksson-Friman, Ana Bosch, Johan Hartman, Susanne Agartz, Gyula Pekar, Tobias Lekberg, Zakaria Einbeigi, Per Grybäck, Claudia Maes, Theodoros Foukakis, Judith Bjöhle
Publikováno v:
JAMA Oncol
Importance Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the potential of T-DM1 as monotherapy is so far unknown. Objective To assess pathologic c
Autor:
Werner Lichtenegger, Georg Heinrich, Inga Bekes, Julia Jückstock, Thomas W. P. Friedl, Robert E. Coleman, Matthias W. Beckmann, Volkmar Müller, Sara Y. Brucker, Ralf Lorenz, Sven Mahner, Wolfgang Janni, Hans Tesch, Andreas Schneeweiss, Tanja Fehm, Lothar Häberle, Helmut Forstbauer, Jens Uwe Blohmer, Visnja Fink, Peter A. Fasching, Jens Huober, Brigitte Rack
Publikováno v:
JAMA Oncol
Importance Bisphosphonate treatment in patients with early breast cancer has become part of care, but the optimal treatment duration is still unclear. Objective To compare 2 vs 5 years of zoledronate treatment following adjuvant chemotherapy in patie
Autor:
Pei Loo Ow, Angel Garcia, Lesley Samuel, Rajarshi Roy, Adam McGeoch, D. Fyfe, W Saku, Simon Aird Grumett, Jonathan Nicoll, Jo Dent, Tom Samuel Waddell, Jo Webster, Christine Allmark, Tania Tillett, Colin Askill, Justin S. Waters, C. Handforth, Erica Beaumont, Vallipuram Vigneswaran, Sharon Ruddock, Nick Wadd, Syed Zubair, Kinnari Patel, Vanessa Potter, Daniel Propper, Olwyn Williams, Marc Jones, Kamalnayan Guptal, Peter Hall, Gareth Griffiths, Joseph Mano, Juan W. Valle, Sheela Rao, David A Cairns, Go Trial Investigators, Eszter Katona, Nick Maisey, Chris Twelves, Daniel Swinson, Nicholas Reed, Heike I. Grabsch, Joanne Askey, Jonathan Wadsley, Tom Roques, Sue Cheeseman, Stephen Falk, Louise Medley, Arshad Jamil, Emma Cattell, Victori Kunene, Matthew R. Sydes, Charles Candish, Claire Hobbs, Rebecca Herbertson, Jo Parkinson, Nicholas S. Reed, Louise Brook, Zuzana Stokes, Mohammed Khan, Ann Crossley, Elin Jones, George Bozas, Sebastian Cummins, Anirban Chatterjee, Michael Bennet, Helen Marshall, Pavel Bezecny, David Sherriff, Matthew T. Seymour, Lauren Gorf, Galina Velikova, Jean Gall, Kamposioras Konstantinos-Velios, Sally Clive, Eleanor James, Fiona Collinson, Dunca Wilkins, Simon Lord, Julia Brown, Serena Hilman, A. Robinson, Richard Ellis, Alaaeldin Shablak, Russell D Petty, Sherif Raouf, Helen Howard
Publikováno v:
Hall, P S, Swinson, D, A. Cairns, D, S. Waters, J, Petty, R, Allmark, C, Ruddock, S, Falk, S, Wadsley, J, Roy, R, Tillett, T, Nicoll, J, Cummins, S, Mano, J, Grumett, S, Stokes, Z, Konstantinos-Velios, K, Chatterjee, A, Garcia, A, Waddell, T, Guptal, K, Maisey, N, Khan, M, Dent, J, Lord, S, Crossley, A, Katona, E, Marshall, H, I. Grabsch, H, Velikova, G, Loo Ow, P, Handforth, C, Howard, H & T. Seymour, M 2021, ' Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal CancerThe GO2 Phase 3 Randomized Clinical Trial ', JAMA Oncology . https://doi.org/10.1001/jamaoncol.2021.0848
JAMA Oncology, 7(6), 869-877. American Medical Association
JAMA Oncology, 7(6), 869-877. American Medical Association
Importance: Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap. Objective: The GO2 randomized clinical trial sought to optimize chemotherapy dosing in older and/or frai
Autor:
C. Dalban, Laurence Gladieff, Jalid Sehouli, Giorgia Mangili, Magali Provansal, Ugo De Giorgi, Isabelle Ray-Coquard, Hans Joachim Lück, Fabien Brocard, Andreas Schnelzer, Sandro Pignata, Keiichi Fujiwara, Annick Chevalier-Place, Philipp Harter, Patricia Pautier, Domenica Lorusso, Pierre Heudel, Ignace Vergote, Anne Floquet, Frédéric Selle
Publikováno v:
JAMA Oncol
Importance To our knowledge, this is the first randomized trial in sex cord-stromal tumors, and it establishes weekly paclitaxel as standard-of-care therapy after platinum-based therapy in this setting. Objective To determine the efficacy of weekly p
Autor:
Tae-You Kim, Jennifer J. Knox, Ho Yeong Lim, Ignacio Melero, Yoon-Koo Kang, Masatoshi Kudo, Francesco Tovoli, Chiun Hsu, Thomas Yau, Jaclyn Neely, Aiwu Ruth He, Ming Mo Hou, Bruno Sangro, Yun Shen, Tami Wisniewski, Jeffrey Anderson, Ana Matilla, Armando Santoro, Bassel F. El-Rayes, Anthony B. El-Khoueiry, Mirelis Acosta-Rivera
Publikováno v:
JAMA Oncol
Importance Most patients with hepatocellular carcinoma (HCC) are diagnosed with advanced disease not eligible for potentially curative therapies; therefore, new treatment options are needed. Combining nivolumab with ipilimumab may improve clinical ou
Autor:
Nina A. Karaseva, Sukrut Shah, Lucjan Wyrwicz, Joseph Chao, Christian Caglevic, Kohei Shitara, Luis Villanueva, Eric Van Cutsem, Al B. Benson, Eray Goekkurt, Wasat Mansoor, Marcelo Garrido, Iveta Kudaba, Keun Wook Lee, Jeeyun Lee, Maria Alsina, Andrew H. Ko, Charles S. Fuchs, S. Peter Kang, Josep Tabernero, Hugo Castro, Hironaga Satake, Uma Kher, Yung-Jue Bang, Maria Ignez Braghiroli, Peter C. Enzinger, Zev A. Wainberg, Hyun Cheol Chung
Publikováno v:
JAMA Oncology. 6:1571
Importance Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. Objective To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alo
Autor:
Zoe B. Ciantra, Shana Criscitiello, Jason I. Kass, Jochen H. Lorch, Roy B. Tishler, Kai W. Wucherpfennig, Glenn J. Hanna, Nicole G. Chau, Adrienne M. Luoma, Ravindra Uppaluri, Danielle N. Margalit, Heather A. Jacene, Donald J. Annino, Anupam M. Desai, Bhupendra Rawal, Brendan Ross, Robert I. Haddad, Vickie Y. Jo, Jason L. Weirather, Ana Lako, Yu-Hui Chen, P.S. Catalano, Jonathan D. Schoenfeld, Hina Shah, Laura A. Goguen, Scott J. Rodig
Publikováno v:
JAMA Oncology. 6:1563
Importance Novel approaches are needed to improve outcomes in patients with squamous cell carcinoma of the oral cavity. Neoadjuvant immunotherapy given prior to surgery and combining programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte
Autor:
Michael Ghadimi, Ethan B. Ludmir, Ralf Hofheinz, Emmanouil Fokas, Bruce D. Minsky, Claus Rödel, Markus Diefenhardt
Publikováno v:
JAMA Oncology. 6:1416
Importance Despite numerous published phase 3 trials, the association of treatment adherence with outcomes for patients with rectal cancer remains largely unexplored. Objective To analyze the association of treatment adherence with disease-free survi
Autor:
Sze Huey Tan, Jibin Li, Mei Lin, Rui You, Guo-Ping Shen, Yi-Shan Wu, Yi-Jun Hua, Rou Jiang, Lin-Quan Tang, Ming-Yuan Chen, Rui Sun, Yu-Long Xie, Li Ling, Yong Chen, Yu-Xiang He, You-Ping Liu, Qiu-Yan Chen, Xiong Zou, Hong-Dan Zhang, Qing Liu, Jing-Yu Cao, Meng-Xia Zhang, Chong-Yang Duan, Melvin L.K. Chua, Yi-Nuan Zhang, Zhi-Qiang Wang, Ai-Hua Zhuang, Pei Yu Huang, Qi Yang, Ling Guo, Hao-Yuan Mo, Hai-Qiang Mai
Publikováno v:
JAMA Oncology. 6:1345
Importance The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) is unclear. Objective To investigate the efficacy and safety of locoregional radiotherapy in de novo mNPC. Design, Setting, and Parti
Autor:
Martin Sökler, Ulrich Keller, Carsten Kobe, Bastian von Tresckow, Andreas Rosenwald, Stephan Mathas, Paul J Bröckelmann, Michael Fuchs, Jasmin Mettler, Julia Meissner, Peter Borchmann, Andrea Kerkhoff, Andreas Zimmermann, Stephanie Sasse, Wolfram Klapper, Helen Goergen, Rainer Ordemann, Andreas Engert, Matthias Bormann, Teresa V Halbsguth, Christian Baues, Andreas Hüttmann
Publikováno v:
JAMA Oncol
Importance In early-stage unfavorable classic Hodgkin lymphoma (cHL), conventional therapy induces high cure rates but also relevant acute and long-term toxic effects. Nivolumab is well tolerated and highly effective in relapsed/refractory cHL but ha